Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Thailand Inflation Remains Negative for 10th Straight Month in January 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SK Bioscience recently inked a contract manufacturing organization (CMO) agreement with MSD which is also known as Merck & Co. The deal is for the production of the next-generation Zaire Ebola virus vaccine candidate.
The Vice Minister of the Ministry of Health and Welfare, Park Min Soo, MSD’s executive vice president Sanat Chattopadhyay, SK Bioscience’s chief executive officer Ahn Jae Yong, SK Disocvery’s vice chairman Chang Won Chey, Hillman Labs CEO, Raman Rao, and Representative of Global R&BD Kim Hoon were all present at the signing ceremony.
After the contract signing of the CMO deal with MSD, The Korea Herald reported that the stock price of SK Bioscience surged by 16.39% to KRW83,100 or about $64.04 late last week. The increase is said to be largely due to the hopes that the deal will improve the company’s slow sales performance.
In any case, SK Bioscience further confirmed the deal with MSD on Monday, May 8. It also provided more details about the CMO agreement today.
“For the growth and development of the biopharmaceutical industry, it is very important to promote cooperation between companies and establish its innovative ecosystem,” Park Min Soo said in a press release. “The Korean government is seeking various support measures, such as regulatory innovation and governance establishment, to promote cooperation between companies. We hope that this contract will continue a friendly cooperative relationship between MSD, Korea, and SK bioscience.”
MSD’s EVP and president of the manufacturing unit, Sanat Chattopadhyay, also said, “At MSD, we continue to seek innovative solutions to help expand access and help make our vaccines available when needed to people around the world. This agreement with SK bioscience, as part of our strong global manufacturing network, may enable us to further assist the global community in its response to future outbreaks of the Zaire Ebola virus.”
